Fig. 1 · Structure

Documents & Downloads

Ibutilide fumarate

Cat. No. A11750 CAS 122647-32-9
Ibutilide is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm. It exerts its antiarrhythmic effect by induction of slow inward sodium current, which prolongs action potential and refractory period (physiology) of myocardial cells.

In Stock

Publications for Ibutilide fumarate

1 publication citing this product

  1. Claudia Alvarez Baron, .et al. , Sci Rep, 2025, Aug 16;15(1):29995 PMID: 40819150

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Ibutilide inhibited recombinant hERG1a potassium current in a four-laboratory manual patch-clamp study. The original source table includes AdooQ Bioscience A11750 for one participating laboratory. Potency estimates varied between laboratories, and the anonymized results cannot be assigned to that supplier. These findings support hERG inhibition under the tested cellular conditions; they do not establish a single product-specific potency or exclude additional ionic actions. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

In Vitro Studies

Multi-laboratory measurement of ibutilide inhibition of recombinant hERG1a

Cell-based study · CHO cells expressing hERG1a (Lab 1) and HEK293 cells expressing hERG1a (Labs 2, 4 and 5); Lab 3 did not participate in Phase 2. [1]

Four laboratories measured ibutilide hERG inhibition. Concentration-corrected potency estimates differed across laboratories; the anonymized lab labels cannot be assigned to named drug sources. These are electrophysiological endpoints, not treatment doses or evidence of clinical efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
hERG1a outward ramp current inhibition, anonymized Lab 1pIC50 7.9277; reported 95% CI column: 0.0347[1]
hERG1a outward ramp current inhibition, anonymized Lab 2pIC50 8.4643; reported 95% CI column: 0.157[1]
hERG1a outward ramp current inhibition, anonymized Lab 4pIC50 8.2481; reported 95% CI column: 0.0742[1]
hERG1a outward ramp current inhibition, anonymized Lab 5pIC50 7.9580; reported 95% CI column: 0.138[1]

Literature-Reported Treatment Conditions

Method
Drug application during manual whole-cell patch clamp at near-physiological temperature: Lab 1, 36 ± 1 °C; Lab 2, 35–38 °C; Lab 4, 36 ± 1 °C; Lab 5, 37 ± 2 °C. Step-ramp stimulus at 0.2 Hz.
Co-treatment
No therapeutic drug combination. E-4031 served as an endpoint current-isolation control (1 µM for the four Phase 2 laboratories).
Reported limits
Ibutilide-specific concentration series, exposure durations, vehicle composition and cell counts were not extracted from raw electrophysiology reports. General request to test at least four concentrations is not an ibutilide-specific verified dose series.
Methods and source locations

Compound reported in the paper: Ibutilide; Compound label in the paper: Ibutilide; source table includes AdooQ Bioscience A11750 and Tocris 3908

Supports ibutilide hERG inhibition in this recombinant cellular assay, including a documented A11750 source contribution. Numerical values belong to anonymized laboratories and are not A11750-specific product potency specifications.

Methods Sec3–6 and Sec8–10; Results Sec17 and Figure 4; Supplementary Material 1 Tables 1, 2, 4 and 6 (Ibutilide rows)

hERG1a outward ramp current inhibition, anonymized Lab 1: Manual whole-cell patch clamp; variable-slope Hill fit using concentration-corrected data. CI is retained as the scalar printed in the table; it is not SD, SEM or sample size. — Supplementary Material 1, Supplemental Table 4, Ibutilide row 22, B22:C22; Methods Sec10 (Estimation of drug potencies)

hERG1a outward ramp current inhibition, anonymized Lab 2: Manual whole-cell patch clamp; variable-slope Hill fit using concentration-corrected data. CI is retained as the scalar printed in the table; it is not SD, SEM or sample size. — Supplementary Material 1, Supplemental Table 4, Ibutilide row 22, D22:E22; Methods Sec10 (Estimation of drug potencies)

hERG1a outward ramp current inhibition, anonymized Lab 4: Manual whole-cell patch clamp; variable-slope Hill fit using concentration-corrected data. CI is retained as the scalar printed in the table; it is not SD, SEM or sample size. — Supplementary Material 1, Supplemental Table 4, Ibutilide row 22, H22:I22; Methods Sec10 (Estimation of drug potencies)

hERG1a outward ramp current inhibition, anonymized Lab 5: Manual whole-cell patch clamp; variable-slope Hill fit using concentration-corrected data. CI is retained as the scalar printed in the table; it is not SD, SEM or sample size. — Supplementary Material 1, Supplemental Table 4, Ibutilide row 22, J22:K22; Methods Sec10 (Estimation of drug potencies)

Specifications

Manufacturer Adooq Bioscience
CAS Number 122647-32-9
Formula (C20H36N2O3S)2.C4H4O
Molecular Weight 885.2
SMILES
CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O.CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O.C(=C/C(=O)O)\C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 88 mg/mL (99.4 mM)
Water 88 mg/mL (99.4 mM)
Ethanol 88 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Claudia Alvarez Baron, Jun Zhao, Huimei Yu, et al. Multi-laboratory comparisons of manual patch clamp hERG data generated using standardized protocols and following ICH S7B Q&A 2.1 best practices. Scientific Reports (2025). PMID: 40819150 DOI: 10.1038/s41598-025-15761-8 Source material

Publications

1 publication citing this product

  1. Claudia Alvarez Baron, .et al. , Sci Rep, 2025, Aug 16;15(1):29995 PMID: 40819150

Added to your cart

View Cart Checkout
Loading...